Table 2.
Comparing Response between the 2 Groups
| Palbociclib n=58 (%) | Ribociclib n=58 (%) | Significance P | |
|---|---|---|---|
| Clinical benefit rate at 3 months | 53 (91.4) | 49 (84.5) | 0.25 |
| Clinical benefit rate at 6 months | 34 (58.6) | 34 (58.6) | |
| Clinical benefit rate at 9 months | 14 (24.1) | 22 (37.9) | 0.1 |
| Clinical benefit rate at 12 months | 8 (13.8) | 10 (17.2) | 0.79 |